Garde Capital Inc. Takes $1.02 Million Position in Becton Dickinson and Co (BDX)

Garde Capital Inc. acquired a new stake in Becton Dickinson and Co (NYSE:BDX) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 5,200 shares of the medical instruments supplier’s stock, valued at approximately $1,019,000.

Other large investors have also made changes to their positions in the company. Family Firm Inc. increased its position in Becton Dickinson and by 0.5% in the 2nd quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock valued at $236,000 after buying an additional 6 shares in the last quarter. Northwest Quadrant Wealth Management LLC increased its position in Becton Dickinson and by 0.4% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock valued at $332,000 after buying an additional 6 shares in the last quarter. Northstar Group Inc. increased its position in Becton Dickinson and by 0.3% in the 2nd quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock valued at $584,000 after buying an additional 9 shares in the last quarter. NBT Bank N A NY increased its position in Becton Dickinson and by 0.3% in the 2nd quarter. NBT Bank N A NY now owns 3,351 shares of the medical instruments supplier’s stock valued at $654,000 after buying an additional 10 shares in the last quarter. Finally, Good Life Advisors LLC increased its position in Becton Dickinson and by 0.6% in the 2nd quarter. Good Life Advisors LLC now owns 2,494 shares of the medical instruments supplier’s stock valued at $491,000 after buying an additional 14 shares in the last quarter. 88.60% of the stock is currently owned by institutional investors.

A number of analysts recently commented on the company. Royal Bank of Canada reaffirmed a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price for the company in a research report on Tuesday, October 31st. Wells Fargo & Company assumed coverage on Becton Dickinson and in a research report on Friday, September 22nd. They issued an “outperform” rating and a $225.00 target price for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research report on Friday, November 3rd. Finally, Morgan Stanley boosted their target price on Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $218.36.

Shares of Becton Dickinson and Co (NYSE BDX) opened at $218.77 on Friday. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. The company has a market capitalization of $49,913.57, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07. Becton Dickinson and Co has a twelve month low of $161.50 and a twelve month high of $229.68.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.12 EPS. sell-side analysts predict that Becton Dickinson and Co will post 10.63 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be issued a dividend of $0.75 per share. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date of this dividend is Thursday, December 7th. Becton Dickinson and’s payout ratio is currently 64.52%.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thelincolnianonline.com/2017/12/15/garde-capital-inc-takes-1-02-million-position-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply